Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA
Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA
Opinion
USCA11 Case: 23-11047 Document: 28-1 Date Filed: 11/09/2023 Page: 1 of 2
[DO NOT PUBLISH] In the United States Court of Appeals For the Eleventh Circuit ____________________ No. 23-11047 Non-Argument Calendar ____________________ IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION.
9:20-md-02924-RLR ___________________________________________________ ERIK ROY HILLESLAND, CHANMEIKA HILL, Interested Parties-Appellants, versus GLENMARK PHARMACEUTICALS, INC. USA, MARLENE GOLDENBERG, APOTEX CORP., MICHAEL MCCANDLESS, USCA11 Case: 23-11047 Document: 28-1 Date Filed: 11/09/2023 Page: 2 of 2
2 Opinion of the Court 23-11047 BRAD ALDRIDGE, et al.,
Defendants-Appellees.
____________________ Appeal from the United States District Court for the Southern District of Florida D.C. Docket No. 9:20-md-02924-RLR ____________________ Before WILSON, JILL PRYOR, and GRANT, Circuit Judges.
PER CURIAM: Upon review of the record and the response to the jurisdic- tional questions, this appeal is DISMISSED for lack of jurisdiction.
Appellant lacks standing to bring this appeal because there is no evidence that he is, or ever was, a plaintiff in this action, and there is no indication that the district court has ever entered an appeala- ble order that caused him injury. See Wolff v. Cash 4 Titles, 351 F.3d 1348, 1353-54 (11th Cir. 2003); Mickles on behalf of herself v. Country Club, Inc., 887 F.3d 1270, 1278 (11th Cir. 2018).
Case-law data current through December 31, 2025. Source: CourtListener bulk data.